Novogene Technology Co., Ltd., a Beijing, China-based commercial provider of genomic services and solutions with next-generation sequencing (NGS) and bioinformatics expertise, completed a $75M [RMB515M] Series B funding.
Backers included China Merchants Bank Co., Ltd.’s CMB International Capital Management (Shenzhen) Co., Ltd., SDIC Innovation Investment Management Co., Ltd. and Shanghai Sigma Square Investment Center LP.
The company intends to use the funds to grow in its global NGS service market and in clinical sequencing R&D and services, as well as to further strengthen its leadership position in the NGS industry.
Led by CEO Dr. Ruiqiang Li, Novogene provides genomic services and solutions with NGS and bioinformatics expertise. The company has 1,300 employees, multiple locations around the world, 43 NGS related patents, and over 200 publications in journal such as Nature and Science.